- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02562781
Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications? (HYPEROXIA)
Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications? A Randomised, Prospective Study in Patients Undergoing Vascular Surgery
Patients undergoing vascular surgery are at a significantly high risk of perioperative cardiovascular, cerebral and renal events compared to those undergoing non-vascular surgery. This could be because of co-morbidities that are common in this patient group. Additionally, smoking, which is common in this population, may be a contributing factor.
Oxygen therapy has been used for decades in order to reduce the risk of myocardial infarction and stroke in patients undergoing vascular surgery and pre-existing co-morbidities in the belief that increased inspired oxygen increases oxygen delivery to tissues, thereby reducing the risk for hypoxia and cell death. However, several studies published recently have questioned the routine use of high inspired oxygen concentration (hyperoxia) to improve oxygen delivery, specifically in the neonatal period but possibly even following myocardial infarction. This could be explained by the fact that increasing inspired concentrations of oxygen cause vasoconstriction in cerebral and coronary arteries, thereby reducing blood flow. Additionally, increased oxygen causes excessive production of reactive oxygen species (ROS), and repercussion injury from oxidative stress. The latter can lead to apoptosis (cell death) in myocardial or cerebral neurons. Despite the high risks of administering oxygen when not needed, it is routinely used in hospitals all over the world without a doctors prescription.
This study aims to assess peri-operative complications up to 1 year following vascular surgery in patients randomised to receive high inspired oxygen concentration (endpoint: SpO2 98 - 100%) or minimal inspired O2 concentration (endpoint: SpO2 > 90%).
Study Overview
Detailed Description
Oxygen is probably one of the commonest "non-prescription" drug used in the hospital and its advantage in several situations including carbon monoxide poisoning, central hypoxia and prior to planned intubation in an acute situation are today well-established and commonly used. Oxygen has been frowned upon in the resuscitation of newborn babies because of the risk of retrolental hypoplasia, now well accepted and adopted in clinical practice. Oxygen has also been traditionally used to increase oxygen carrying capacity in patients presenting with an acute coronary syndrome (ACS), to reduce surgical site infections (SSI), to ensure adequate oxygen delivery to tissues in unconscious patients, during cardiac surgery and for postoperative management, specifically after major surgery. Thus, deliberate use of high inspiratory oxygen concentrations (e.g., 80% or above) is recommended in the treatment of specific intoxications, such as with carbon monoxide or cyanide, wherein hyperbaric oxygen should also be considered. In addition, a high oxygen fraction has been suggested to prevent adverse outcomes after surgery and anesthesia, including a reduction in wound infections and postoperative nausea and vomiting (PONV). In critically ill patients, oxygen delivery to the tissues is often compromised, and supplemental oxygen (e.g., face mask with 10 L oxygen per min) is commonly administered to patients with pneumonia, sepsis, acute coronary syndrome, or stroke - in fact, it is estimated that oxygen is given during transport in approximately one-third of all ambulance journeys.
Several reports published recently have questioned many of the "routine" uses of oxygen and some evidence even seems to point towards negative outcomes in some of these conditions. Specifically, excessive oxygen is likely to do more harm than good in the neonatal period, following cardio-pulmonary resuscitation and likely following acute myocardial infarction. Prospective, randomised studies on this important use of oxygen in the preoperative string are, however, lacking in the literature and in view of theoretical risks for hyperoxemia to several organs, the routine use of high oxygen fractions during the peri-operative phase can be questioned.
This study aims to assess peri-operative complications up to 1 year following vascular surgery in patients randomised to receive high inspired oxygen concentration (endpoint: SpO2 98 - 100%) or minimal inspired O2 concentration (endpoint: SpO2 > 90%).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Örebro, Sweden, 701 85
- University Hospital
-
Örebro, Sweden, 70185
- Örebro University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients undergoing elective vascular surgery (peripheral or aortic surgery),
- No language or cognitive disability
- Written, informed consent
Exclusion Criteria:
- Patients with COPD/other lung diseases that require preoperative oxygen therapy
- Patients undergoing carotid artery surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Supplemental Oxygen
Inspired oxygen fraction > 0.5 and SpO2 = 98-100%
|
Oxygen in sufficient quantity to maintain SpO2 > 98%
Other Names:
Supplemental Oxygen in sufficient quantity to maintain SpO2 > 90%
Other Names:
|
|
Experimental: Air or supplemental oxygen
Air or lowest possible inspired concentration of oxygen to maintain SpO2 > 90%
|
Oxygen in sufficient quantity to maintain SpO2 > 98%
Other Names:
Supplemental Oxygen in sufficient quantity to maintain SpO2 > 90%
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite morbidity
Time Frame: 0 - 1 month postoperatively
|
Major complications such as MACE, TIA/stroke/renal insufficiency/POCD etc
|
0 - 1 month postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Long term outcome (Major complications)
Time Frame: 1 month to 1 year postoperatively
|
Major complications
|
1 month to 1 year postoperatively
|
|
Specific outcomes (Major adverse cardiac events (MACE))
Time Frame: 0 - 1 year postoperatively
|
Major adverse cardiac events (MACE)
|
0 - 1 year postoperatively
|
|
Specific outcomes (TIA or stroke)
Time Frame: 0 - 1 year postoperatively
|
TIA or stroke
|
0 - 1 year postoperatively
|
|
Specific outcomes (renal insufficiency including dialysis or renal failure)
Time Frame: 0 - 1 year postoperatively
|
renal insufficiency including dialysis or renal failure
|
0 - 1 year postoperatively
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complication (Re-operation or bleeding)
Time Frame: 0 - 30 days postoperatively
|
Re-operation or bleeding
|
0 - 30 days postoperatively
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anil Gupta, MD, PhD, Örebro University, Sweden
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ÖrebroU
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vascular Disease
-
The Methodist Hospital Research InstituteNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPeripheral Vascular DiseasesUnited States
-
SensomeCompletedPeripheral Vascular DiseaseBelgium
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Rijnstate HospitalCompletedPeripheral Vascular DiseasesNetherlands
-
University of West FloridaNational Institute on Aging (NIA)CompletedArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
Abbott Medical DevicesCompletedCardiovascular Disease | Peripheral Vascular DiseaseUnited States
-
Unity Health TorontoUnknownPeripheral Vascular Disease Patient
-
Horizons International Peripheral GroupAdvanced Catheter Therapies, Inc.CompletedCardiovascular Disease | Peripheral Arterial Disease | Peripheral Vascular DiseaseUnited States
-
Boston Scientific CorporationRecruitingPeripheral Vascular DiseasesUnited States, Australia, Taiwan, Thailand, Austria, Germany, Canada, France, China, Spain, Poland
Clinical Trials on Oxygen
-
Hospital Universitario 12 de OctubreActive, not recruitingAirway ObstructionSpain
-
National Baromedical ServicesMayo Clinic; Dartmouth-Hitchcock Medical Center; Eastern Virginia Medical School and other collaboratorsCompletedCarcinoma, Squamous Cell | Cancer of the Head and NeckUnited States
-
Aalborg University HospitalUniversity of AarhusUnknownCardiac Surgery | Cardiopulmonary Bypass | Acute Lung Injury | Hyperoxia | Oxygen ToxicityDenmark
-
Chang, Steve S., M.D.Santa Barbara Cottage HospitalCompletedPostoperative AbscessUnited States
-
Princess Margaret Hospital for ChildrenCompleted
-
Royal Brompton & Harefield NHS Foundation TrustLiverpool University Hospitals NHS Foundation Trust; National Institute for...CompletedLung; Disease, Fibroid (Chronic)United Kingdom
-
Heidelberg UniversityCompletedPulmonary Arterial Hypertension | Oxygen Deficiency | CTEPHGermany
-
Aalborg University HospitalRigshospitalet, Denmark; Copenhagen Trial Unit, Center for Clinical Intervention...CompletedHypoxemic Respiratory Failure | Oxygen ToxicityUnited Kingdom, Denmark, Finland, Iceland, Netherlands, Norway, Switzerland
-
University Hospital Plymouth NHS TrustCompletedSepsisUnited Kingdom
-
UMC UtrechtThe Netherlands Cancer InstituteCompletedBreast Cancer | Radiation ToxicityNetherlands